Naredi najboljše naložbe svojega življenja
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Zagotovite si že od 2 evrov
Analiza delnic
Profil

Regeneron Pharmaceuticals Delnica

REGN
US75886F1075
881535

Tečaj

1.131,50
Danes +/-
-17,19
Danes %
-1,67 %
P

Regeneron Pharmaceuticals delniški tečaj

%
Tedensko
Podrobnosti

Kurs

ⓘ

Pregled

Grafikon cen delnic nudi podrobne in dinamične vpoglede v zmogljivost delnice Regeneron Pharmaceuticals ter prikazuje agregirane cene dnevno, tedensko ali mesečno. Uporabniki lahko izbirajo med različnimi časovnimi okvirji, da natančno analizirajo zgodovino delnice in sprejmejo obveščene investicijske odločitve.

Intradnevna funkcija

Intradnevna funkcija zagotavlja podatke v realnem času in investitorjem omogoča, da spremljajo nihanja cen delnic Regeneron Pharmaceuticals tekom trgovalnega dne, za sprejemanje pravočasnih in strateških investicijskih odločitev.

Skupni donos in relativna sprememba cene

Oglejte si skupni donos delnice Regeneron Pharmaceuticals, da ocenite njeno donosnost skozi čas. Relativna sprememba cene, ki temelji na prvi razpoložljivi ceni v izbranem časovnem okvirju, ponuja vpoglede v zmogljivost delnice in pomaga pri oceni njenega investicijskega potenciala.

Interpretacija in investiranje

Izkoristite obsežne podatke, ki so predstavljeni na grafikonu cen delnic, da analizirate tržne trende, gibanje cen in potencialne donose od delnice Regeneron Pharmaceuticals. Sprejmite obveščene investicijske odločitve z primerjavo različnih časovnih okvirov in oceno intradnevnih podatkov za optimizirano upravljanje portfelja.

Regeneron Pharmaceuticals Zgodovina tečajev

DatumRegeneron Pharmaceuticals Delniški tečaj
6. 9. 20241.131,50 undefined
5. 9. 20241.150,56 undefined
4. 9. 20241.179,37 undefined
3. 9. 20241.168,81 undefined
30. 8. 20241.184,69 undefined
29. 8. 20241.178,93 undefined
28. 8. 20241.199,29 undefined
27. 8. 20241.201,76 undefined
26. 8. 20241.199,37 undefined
23. 8. 20241.199,12 undefined
22. 8. 20241.187,66 undefined
21. 8. 20241.185,34 undefined
20. 8. 20241.192,23 undefined
19. 8. 20241.196,88 undefined
16. 8. 20241.179,31 undefined
15. 8. 20241.175,33 undefined
14. 8. 20241.156,86 undefined
13. 8. 20241.158,33 undefined
12. 8. 20241.121,09 undefined

Regeneron Pharmaceuticals delnica promet, EBIT, dobiček

  • 3 leta

  • 5 let

  • 10 let

  • 25 let

  • Max

Prihodki
EBIT
Dobiček
Podrobnosti

Prihodki, dobiček & EBIT

ⓘ

Razumevanje prihodkov, EBIT in dohodka

Pridobite vpoglede v Regeneron Pharmaceuticals, obširni pregled finančne uspešnosti lahko dobite z analizo grafov prihodkov, EBIT in dohodka. Prihodki predstavljajo skupni dohodek, ki ga Regeneron Pharmaceuticals pridobi iz svojih glavnih poslovnih dejavnosti in prikazuje sposobnost podjetja za pridobivanje in ohranjanje strank. EBIT (Dobiček pred obrestmi in davki) podaja informacije o operativni donosnosti podjetja, neobremenjene s stroški davkov in obresti. Razdelek dohodka odraža čisti dobiček Regeneron Pharmaceuticals, končno merilo za njegovo finančno zdravje in dobičkonosnost.

Letna analiza in primerjave

Oglejte si letne stolpce, da razumete letno uspešnost in rast Regeneron Pharmaceuticals. Primerjajte prihodke, EBIT in dohodek, da ocenite učinkovitost in donosnost podjetja. Višji EBIT v primerjavi z lanskim letom kaže na izboljšanje operativne učinkovitosti. Podobno povečanje dohodka nakazuje na povečano skupno donosnost. Analiza leta-za-letom primerjave pomaga vlagateljem pri razumevanju rasti in operativne učinkovitosti podjetja.

Uporaba pričakovanj za investicije

Pričakovane vrednosti za prihajajoča leta ponujajo vlagateljem vpogled v pričakovano finančno uspešnost Regeneron Pharmaceuticals. Analiza teh napovedi skupaj s historičnimi podatki prispeva k sprejemanju utemeljenih investicijskih odločitev. Vlagatelji lahko ocenijo potencialna tveganja in donose ter usmerijo svoje investicijske strategije ustrezno, da optimizirajo donosnost in zmanjšajo tveganja.

Investicijski vpogledi

Primerjava med prihodki in EBIT pomaga oceniti operativno učinkovitost Regeneron Pharmaceuticals, medtem ko primerjava prihodkov in dohodka razkriva neto donosnost po upoštevanju vseh stroškov. Vlagatelji lahko pridobijo dragocene vpoglede z natančno analizo teh finančnih parametrov in tako postavijo temelje za strateške investicijske odločitve, da izkoristijo potencial rasti Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals Prihodki, dobiček in zgodovina EBIT

DatumRegeneron Pharmaceuticals PrihodkiRegeneron Pharmaceuticals EBITRegeneron Pharmaceuticals Dobiček
2029e20,08 milijard undefined0 undefined8,14 milijard undefined
2028e18,94 milijard undefined7,89 milijard undefined7,38 milijard undefined
2027e17,88 milijard undefined7,19 milijard undefined6,78 milijard undefined
2026e16,75 milijard undefined6,44 milijard undefined6,17 milijard undefined
2025e15,69 milijard undefined5,72 milijard undefined5,50 milijard undefined
2024e14,45 milijard undefined5,15 milijard undefined5,07 milijard undefined
202313,12 milijard undefined4,34 milijard undefined3,95 milijard undefined
202212,17 milijard undefined4,99 milijard undefined4,34 milijard undefined
202116,07 milijard undefined8,95 milijard undefined8,08 milijard undefined
20208,50 milijard undefined3,58 milijard undefined3,51 milijard undefined
20197,86 milijard undefined2,21 milijard undefined2,12 milijard undefined
20186,71 milijard undefined2,53 milijard undefined2,44 milijard undefined
20175,87 milijard undefined2,08 milijard undefined1,20 milijard undefined
20164,86 milijard undefined1,33 milijard undefined896,00 mio. undefined
20154,10 milijard undefined1,25 milijard undefined636,00 mio. undefined
20142,82 milijard undefined823,00 mio. undefined338,00 mio. undefined
20132,11 milijard undefined760,00 mio. undefined424,00 mio. undefined
20121,38 milijard undefined458,00 mio. undefined750,00 mio. undefined
2011446,00 mio. undefined−205,00 mio. undefined−222,00 mio. undefined
2010459,00 mio. undefined−97,00 mio. undefined−104,00 mio. undefined
2009379,00 mio. undefined−74,00 mio. undefined−68,00 mio. undefined
2008238,00 mio. undefined−87,00 mio. undefined−79,00 mio. undefined
2007125,00 mio. undefined−115,00 mio. undefined−107,00 mio. undefined
200663,00 mio. undefined−108,00 mio. undefined−102,00 mio. undefined
200566,00 mio. undefined−124,00 mio. undefined−95,00 mio. undefined
2004174,00 mio. undefined6,00 mio. undefined42,00 mio. undefined

Regeneron Pharmaceuticals Delniški kazalniki

  • Preprosto

  • Razširjeno

  • Izkaz poslovnega izida

  • Bilančni prikaz

  • Denarni tok

 
PROMET (milijard)PRIHODKI OD RASTI (%)BRUTO MARŽA (%)BRUTO DOHODEK (milijard)EBIT (milijard)EBIT-MARŽA (%)ČISTI DOBIČEK (milijard)Rast dobička (%)ŠTEVILO DELNIC (mio.)DOKUMENTI
1988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00,000,000,010,010,010,020,020,020,030,040,030,060,020,020,060,170,070,060,130,240,380,460,451,382,112,824,104,865,876,717,868,5016,0712,1713,1214,4515,6916,7517,8818,9420,08
--300,0075,00--200,0014,29−16,6735,0040,74−10,5373,53−62,71-159,09205,26−62,07−4,5598,4190,4059,2421,11−2,83208,9752,7633,9745,5318,4220,8214,2917,178,0689,15−24,267,7510,168,606,766,725,976,01
-------100,0095,0088,8986,8491,1874,5868,1872,7389,4791,3886,3687,30100,00100,0099,7499,5699,1093,9092,5992,7390,4293,8593,2493,5390,0586,8284,8387,1886,93------
00000000,020,020,020,030,030,040,020,020,050,160,060,060,130,240,380,460,441,291,952,623,714,565,486,287,087,3813,6310,6111,40000000
−0,00−0,00−0,00−0,01−0,02−0,04−0,02−0,01−0,02−0,01−0,01−0,02−0,03−0,09−0,12−0,100,01−0,12−0,11−0,12−0,09−0,07−0,10−0,210,460,760,821,251,332,082,532,213,588,954,994,345,155,726,447,197,890
-−400,00−100,00−142,86−328,57−600,00−104,76−45,83−110,00−51,85−34,21−70,59−42,37−395,45−554,55−175,443,45−187,88−171,43−92,00−36,55−19,53−21,13−45,9633,2436,1029,1830,5127,3935,4237,7628,1142,1055,6741,0333,0535,6536,4838,4440,2441,62-
−0,00−0,00−0,00−0,00−0,02−0,04−0,03−0,02−0,03−0,01−0,01−0,02−0,02−0,08−0,12−0,110,04−0,10−0,10−0,11−0,08−0,07−0,10−0,220,750,420,340,640,901,202,442,123,518,084,343,955,075,506,176,787,388,14
-200,00-33,33375,00110,53−22,50−22,5833,33−62,50−25,00155,56-230,4363,16−13,71−139,25−326,197,374,90−26,17−13,9252,94113,46−437,84−43,47−20,2888,1740,8833,82103,84−13,4266,02129,86−46,28−8,8828,138,6712,109,828,9710,25
10,0014,0015,0015,0015,0017,0019,0020,0024,0029,0031,0031,0035,0042,0044,0050,0056,0056,0058,0066,0079,0080,0083,0091,00115,00111,00113,00115,00116,00116,00115,00115,00115,00112,00114,00113,70000000
------------------------------------------
Podrobnosti

GuV

ⓘ

Promet in rast

Regeneron Pharmaceuticals Promet in njegova rast sta ključna za razumevanje finančnega zdravja in operativne učinkovitosti podjetja. Konstantno povečevanje prometa nakazuje na sposobnost podjetja, da učinkovito trži in prodaja svoje izdelke ali storitve, medtem ko odstotek rasti prometa daje vpogled v hitrost, s katero podjetje raste skozi leta.

Bruto marža

Bruto marža je ključni dejavnik, ki prikazuje odstotek prometa nad proizvodnimi stroški. Višja bruto marža namiguje na učinkovitost podjetja pri nadzoru proizvodnih stroškov in obeta potencialno dobičkonosnost in finančno stabilnost.

EBIT in EBIT-marža

EBIT (Earnings Before Interest and Taxes) in EBIT-marža nudita globok vpogled v dobičkonosnost podjetja, brez vpliva obresti in davkov. Vlagatelji pogosto ocenjujejo te metrike, da bi ovrednotili operativno učinkovitost in inherentno dobičkonosnost podjetja, neodvisno od njegove finančne strukture in davčnega okolja.

Dohodek in rast

Neto dohodek in njegova nadaljnja rast sta za vlagatelje nujna, da razumejo dobičkonosnost podjetja. Konstantna rast dohodka poudarja sposobnost podjetja, da poveča svojo dobičkonosnost skozi čas in odraža operativno učinkovitost, strateško konkurenčnost in finančno zdravje.

Izdane delnice

Izdane delnice se nanašajo na skupno število delnic, ki jih je podjetje izdalo. To je ključno za izračun pomembnih kazalnikov, kot je dobiček na delnico (EPS), kar je za vlagatelje ključno za ocenjevanje dobičkonosnosti podjetja na podlagi posamezne delnice in zagotavlja bolj podroben pregled finančnega zdravja in vrednotenja podjetja.

Interpretacija letnega primerjanja

Primerjava letnih podatkov vlagateljem omogoča, da identificirajo trende, ocenijo rast podjetja in napovejo potencialno prihodnjo uspešnost. Analiza, kako se kazalci, kot so promet, dohodek in marže, spreminjajo iz leta v leto, lahko nudi dragocene vpoglede v operativno učinkovitost, konkurenčnost in finančno zdravje podjetja.

Pričakovanja in napovedi

Vlagatelji pogosto primerjajo trenutne in pretekle finančne podatke s tržnimi pričakovanji. Ta primerjava pomaga pri ocenjevanju, ali podjetje Regeneron Pharmaceuticals deluje pričakovano, podpovprečno ali nadpovprečno, in zagotavlja ključne podatke za investicijske odločitve.

 
AKTIVASTANJE GOTOVINE (milijard)TERJATVE (milijard)S. TERJATVE (mio.)ZALOGE (milijard)Kratkoročna sredstva (mio.)OBRATNA SREDSTVA (milijard)OSNOVNA SREDSTVA (milijard)DOLGOROČ. INVEST. (milijard)LANGF. FORDER. (mio.)IMAT. PREMOŽENJSKA VREDNOST (milijard)DOBRA VOLJA (mio.)S. ANLAGEVER. (milijard)OSNOVNA SREDSTVA (milijard)SKUPNA AKTIVA (milijard)PASIVAOBIČAJNE DELNICE (mio.)KAPITALSKA REZERVA (milijard)REZERVE IZ DOBIČKA (milijard)S. LASTNI KAP. (mio.)N. REAL. TEČAJEV/-V. (mio.)LASTNIŠKI KAPITAL (milijard)OBVEZNOSTI (milijard)REZERVACIJA (milijard)KRATKOROČNE OBVEZNOSTI (mio.)KRATKOROČNE OBVEZNOSTI (mio.)LANGF. TUJI KAPITAL (mio.)KRATKOR. TERJ. (milijard)LANGF. VERBIND. (milijard)LATENTNI DAVKI (mio.)S. POVEZANO (mio.)LANGF. VERBIND. (milijard)TUJE KAPITAL (milijard)SKUPAJ KAPITAL (milijard)
19891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                                     
0,010,020,100,080,090,050,050,080,090,090,070,120,390,260,290,300,300,460,770,480,340,250,530,310,690,901,051,041,412,813,213,595,707,7410,84
00000,000,000,000,000,010,010,000,010,000,000,020,040,040,010,010,030,060,080,100,690,960,981,471,611,972,242,674,126,045,335,67
001,001,001,00000000000001,0004,002,003,0000000000000000
00000000000,010,000,000,010,010,000,0000000,000,020,030,070,130,240,400,731,151,421,921,952,402,58
001,0002,00001,001,001,002,001,002,002,002,002,003,003,0013,0011,0019,0025,0019,00176,0078,00125,00164,00131,00225,00243,00387,00161,00332,00411,00386,60
0,010,020,110,080,090,050,050,090,100,090,070,140,390,280,320,340,340,470,800,520,430,360,671,211,802,132,923,184,346,457,699,7814,0215,8819,48
0,000,000,010,010,020,030,030,030,030,030,040,040,040,080,080,070,060,050,060,140,260,350,370,380,530,971,592,082,362,582,893,223,483,764,22
000000,010,020,020,040,030,030,040,050,030,070,050,020,060,080,050,050,370,280,270,390,460,630,861,491,803,313,206,886,645,47
00000000000000000000000000000000000
000,000,00000000000000000000000000000000,921,04
00000000000000000000000000000000000
00000,000,000,00000000,010,010,010,010,000,000,000,010,010,010,010,220,240,270,470,850,580,910,910,971,062,012,87
0,000,000,010,010,030,040,050,050,070,060,060,070,100,120,160,130,080,120,140,200,320,730,660,871,151,712,693,794,435,297,127,3911,4213,3313,60
0,010,020,110,100,120,090,090,140,170,160,140,210,500,390,480,470,420,580,940,720,741,091,322,082,953,845,616,978,7611,7414,8017,1725,4429,2233,08
                                                                     
7,007,00000000000000000000000000000000000,10
0,000,020,120,120,170,170,190,270,310,310,310,410,570,570,670,680,700,901,251,301,341,581,761,762,052,453,103,033,513,914,436,728,099,9511,35
−0,00−0,01−0,01−0,03−0,07−0,10−0,13−0,16−0,17−0,18−0,20−0,22−0,30−0,42−0,53−0,49−0,59−0,69−0,79−0,87−0,94−1,05−1,27−0,52−0,090,220,851,752,955,257,3810,8918,9723,3127,26
00000−1,00−1,00−1,00−1,0000−1,00−2,00−3,00−4,00−3,00−1,000001,00−2,00−2,00−1,00−1,0052,009,00−13,001,00−12,0021,0029,00−26,00−239,00−80,90
00000000000000000000000000000000000
0,010,020,110,090,100,070,070,110,140,130,110,180,270,150,140,180,110,220,460,420,400,530,491,251,952,723,964,776,469,1511,8317,6427,0333,0238,53
00,000,000,000,010,010,010,000,010,010,010,010,020,030,020,020,020,010,010,020,020,020,030,040,060,100,140,140,180,220,420,480,560,594,43
000,000,0000000000000000,010,020,020,030,030,070,070,190,380,500,510,640,751,041,501,882,072,36
01,001,001,001,0010,003,004,004,003,005,004,007,0010,0040,0015,0017,0024,0047,0048,0045,0055,0053,0051,0047,00171,00167,00471,00321,00473,00641,00720,00768,00478,00458,90
0000000000000014,0000000000000000000000
0001,002,003,003,004,002,001,001,001,00000000200,0000001,001,0000127,000000720,0000
00,000,000,010,010,020,010,010,010,010,010,010,020,040,070,030,040,050,280,080,090,110,150,160,300,660,811,241,141,442,102,703,933,147,24
0,010,010,000,010,010,010,010,010,000,000,000,000,200,200,200,200,200,2000,050,110,160,440,460,510,460,360,350,700,710,712,701,982,702,70
00000000000000000000000000000000000
0000007,0013,0015,0013,0011,0010,007,005,0069,0056,0069,00123,00192,00165,00142,00293,00255,00216,00196,00175,00780,00931,00781,00826,00905,00745,00754,00708,00980,80
0,010,010,000,010,010,010,010,020,020,020,010,010,210,210,270,260,270,320,190,220,250,450,690,670,700,631,141,281,481,541,623,442,733,413,68
0,010,010,010,010,020,030,030,030,030,030,030,030,230,250,340,290,310,370,480,300,350,560,840,841,001,291,952,522,622,983,726,146,676,5510,93
0,010,030,110,100,120,090,090,140,170,160,140,210,500,390,480,470,420,580,940,730,741,091,332,082,954,015,927,299,0812,1315,5523,7833,7039,5749,46
Podrobnosti

Bilanca

ⓘ

Razumevanje bilance

Bilanca podjetja Regeneron Pharmaceuticals nudi podroben finančni pregled in prikazuje sredstva, obveznosti in kapital v določenem trenutku. Analiza teh komponent je ključnega pomena za vlagatelje, ki želijo razumeti finančno zdravje in stabilnost podjetja Regeneron Pharmaceuticals.

Sredstva

Sredstva podjetja Regeneron Pharmaceuticals predstavljajo vse, kar ima podjetje v lasti ali nadzira, in ima denarno vrednost. Ločena so na tekoča in osnovna sredstva, kar omogoča vpogled v likvidnost in dolgoročne naložbe podjetja.

Obveznosti

Obveznosti so obveznost, ki jih bo podjetje Regeneron Pharmaceuticals moralo poravnati v prihodnosti. Analiza razmerja med obveznostmi in sredstvi daje informacije o finančni vzvodu in izpostavljenosti tveganju podjetja.

Kapital

Kapital se nanaša na preostali interes v sredstvih podjetja Regeneron Pharmaceuticals po odštetju obveznosti. Predstavlja lastniški delež na sredstva in prihodke podjetja.

Analiza iz leta v leto

Primerjava bilančnih podatkov iz leta v leto vlagateljem omogoča spoznavanje trendov, vzorcev rasti in potencialnih finančnih tveganj ter sprejemanje informiranih investicijskih odločitev.

Interpretacija podatkov

Podrobna analiza sredstev, obveznosti in kapitala lahko investitorjem zagotovi celovit vpogled v finančno stanje podjetja Regeneron Pharmaceuticals, kar jim pomaga pri ocenjevanju naložb in ocenah tveganj.

 
NETO DOHODEK (milijard)AMORTIZACIJA (mio.)ODLOŽENI DAVKI (mio.)SPREMEMBE OBRATNEGA KAPITALA (mio.)POSTAVKE BREZ GOTOVINE (milijard)PLAČANE OBRESTI (mio.)PLAČANI DAVKI (milijard)NETO DENARNI TOK IZ POSLOVANJA (milijard)KAPITALNI ODHODKI (mio.)DENARNI TOK IZ INVESTICIJSKE DEJAVNOSTI (mio.)DENARNI TOK IZ DRUGIH INVESTICIJSKIH DEJAVNOSTI (mio.)OBRESTNI PRIHODKI IN ODHODKI (mio.)NETO SPREMEMBA ZADOLŽENOSTI (milijard)NETO SPREMEMBA LASTNIŠKEGA KAPITALA (mio.)DENARNI TOK IZ FINANČNIH DEJAVNOSTI (mio.)DENARNI TOK IZ DRUGIH FINANČNIH DEJAVNOSTI (mio.)SKUPAJ IZPLAČANE DIVIDENDE (mio.)NETO SPREMEMBA V DENARNEM TOKU (mio.)PROSTI DENARNI TOK (mio.)KOMPENZACIJA NA OSNOVI DELNIC (mio.)
198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
−0,00−0,00−0,00−0,00−0,02−0,04−0,03−0,02−0,03−0,01−0,01−0,02−0,02−0,08−0,12−0,110,04−0,10−0,10−0,11−0,08−0,07−0,10−0,220,750,420,340,640,901,202,442,123,518,084,343,95
00002,003,004,005,006,004,003,003,004,006,008,0012,0015,0015,0014,0011,0011,0014,0019,0031,0036,0041,0052,0074,00104,00145,00148,00210,00235,00286,00341,00421,00
000000000000000000000000−340,0063,00−53,00−121,00−360,00318,00−140,00−130,0075,00−147,00−746,00−837,00
001,00−1,001,000−4,00−14,00−8,00−2,00−7,001,00−15,0011,003,0084,00−58,0027,0093,0088,00−56,00−49,00140,00−18,00−672,00−190,0015,00229,00240,00−926,00−697,00−200,00−1.503,00−1.916,00−243,00−94,00
00−0,00−0,00−0,000,000,010,010,010,000,000,000,010,000,000,00−0,020,020,020,060,070,060,080,120,250,460,720,971,161,080,870,900,731,392,052,04
000001,001,001,0000000011,0011,0011,0011,0011,0011,009,002,0012,0014,0021,0023,0020,0010,005,0018,0022,0025,0023,0055,0053,0073,00
000000000000000000000,0000000,000,060,280,480,750,210,340,191,221,500,87
0−0,00−0,00−0,01−0,02−0,03−0,02−0,02−0,02−0,01−0,01−0,01−0,03−0,06−0,11−0,01−0,02−0,030,020,03−0,09−0,070,10−0,14−0,070,580,751,331,491,312,202,432,627,085,014,59
00−2,00−1,00−3,00−11,00−6,00−3,00−8,00−2,00−3,00−5,00−6,00−8,00−34,00−29,00−6,00−5,00−2,00−18,00−34,00−97,00−99,00−57,00−49,00−156,00−333,00−677,00−511,00−272,00−383,00−429,00−614,00−551,00−1.616,00−926,00
0−2,00−2,00−77,008,00−19,0031,007,00−44,00−38,002,0017,00−57,00−75,00−58,00−49,0010,00115,00−155,00−85,0030,00−2,00−437,00128,00−81,00−355,00−420,00−907,00−1.046,00−1.005,00−1.463,00−2.027,00−70,00−5.384,00−3.784,00−3.185,00
0−1,000−75,0011,00−8,0038,0010,00−35,00−36,005,0022,00−51,00−67,00−24,00−20,0016,00120,00−152,00−67,0065,0095,00−337,00185,00−31,00−199,00−87,00−229,00−534,00−732,00−1.079,00−1.598,00544,00−4.832,00−2.167,00−2.258,00
000000000000000000000000000000000000
00000−0,000−0,00−0,00−0,00−0,00−0,00−0,000,1900,010,00000−0,200,020,050,39−0,00−0,00−0,22−0,14−0,040,04001,98000
6,004,0014,0091,00051,00023,0070,0043,0001,0094,00158,002,0094,0004,00185,00319,007,008,00200,00137,0063,0057,00126,00206,00126,00240,00110,00−64,00−3.271,0026,00−563,00−1.089,00
6,0010,0015,0091,00049,00019,0066,0039,00−1,00092,00349,001,00108,004,004,00185,00319,00−192,0031,00243,00384,00−97,0077,00−218,00−262,00−700,00−24,00−77,00−252,00−1.970,00−1.005,00−1.009,00−1.790,00
05,0000000000000000000000−3,00−142,00−159,0021,00−122,00−328,00−786,00−301,00−187,00−188,00−680,00−1.032,00−445,00−700,00
000000000000000000000000000000000000
5,004,009,007,00−9,00−3,0011,009,001,00−5,00−9,003,007,00216,00−167,0052,00−2,0089,0053,00261,00−251,00−40,00−94,00371,00−253,00305,00113,00160,00−261,00277,00655,00150,00577,00690,00221,00−381,00
−1,40−3,80−5,20−9,10−20,20−44,90−27,40−21,50−28,90−8,20−13,20−19,20−34,40−65,50−144,90−35,80−23,10−35,3020,309,00−124,00−167,20−0,50−198,90−123,90427,30419,40652,90974,001.034,501.812,002.000,402.003,506.529,403.398,003.667,60
000000000000000000000000000000000000

Regeneron Pharmaceuticals Delež marže

Regeneron Pharmaceuticals analiza marž prikazuje bruto maržo, EBIT maržo ter neto maržo dobička podjetja Regeneron Pharmaceuticals. EBIT marža (EBIT/promet) pove, kolikšen odstotek prometa ostane kot operativni dobiček. Neto marža dobička prikazuje, kolikšen odstotek prometa podjetja Regeneron Pharmaceuticals ostane.

  • 3 leta

  • 5 let

  • 10 let

  • 25 let

  • Max

Bruto marža
EBIT-marža
Marža dobička
Podrobnosti

Marže

ⓘ

Razumevanje bruto marže

Bruto marža, izražena v odstotkih, prikazuje brutto dobiček od prodaje Regeneron Pharmaceuticals. Višji odstotek bruto marže pomeni, da Regeneron Pharmaceuticals zadrži več prihodkov, potem ko so upoštevani stroški prodanih blaga. Investitorji uporabljajo ta kazalnik za ocenjevanje finančnega zdravja in operativne učinkovitosti ter za primerjavo z konkurenco in povprečji v panogi.

Analiza marže EBIT

Marža EBIT predstavlja dobiček Regeneron Pharmaceuticals pred obrestmi in davki. Analiza marže EBIT čez različna leta ponuja vpogled v operativno dobičkonosnost in učinkovitost, brez vpliva finančnega vzvoda in davčne strukture. Rastoča marža EBIT čez leta signalizira izboljšano operativno delovanje.

Razumevanje marže prihodkov

Marža prihodkov kaže celoten prihodek, ki ga Regeneron Pharmaceuticals ustvari. Z letno primerjavo marže prihodkov lahko investitorji ocenijo rast in tržno širitev Regeneron Pharmaceuticals. Pomembno je, da se marža prihodkov primerja z bruto maržo in maržo EBIT, da se bolje razume strukturo stroškov in dobička.

Interpretacija pričakovanj

Pričakovane vrednosti za bruto marže, EBIT in marže prihodkov nudijo finančni pogled v prihodnost Regeneron Pharmaceuticals. Investitorji bi morali te pričakovanja primerjati z zgodovinskimi podatki, da bi razumeli potencialno rast in dejavnike tveganja. Ključno je upoštevati osnovne predpostavke in metode, uporabljene pri napovedovanju teh pričakovanih vrednosti, da lahko sprejemajo informirane investicijske odločitve.

Primerjalna analiza

Primerjava bruto marž, EBIT in marž prihodkov, tako letno kot čez večletno obdobje, investitorjem omogoča, da izvedejo temeljito analizo finančnega zdravja in rasti možnosti Regeneron Pharmaceuticals. Ocenjevanje trendov in vzorcev v teh maržah pomaga prepoznati prednosti, slabosti in potencialne investicijske priložnosti.

Regeneron Pharmaceuticals Zgodovina marže

Regeneron Pharmaceuticals Bruto maržaRegeneron Pharmaceuticals Marža dobičkaRegeneron Pharmaceuticals EBIT-maržaRegeneron Pharmaceuticals Marža dobička
2029e86,94 %0 %40,54 %
2028e86,94 %41,62 %38,98 %
2027e86,94 %40,24 %37,91 %
2026e86,94 %38,44 %36,83 %
2025e86,94 %36,48 %35,08 %
2024e86,94 %35,65 %35,06 %
202386,94 %33,05 %30,14 %
202287,18 %41,03 %35,64 %
202184,83 %55,67 %50,24 %
202086,82 %42,10 %41,34 %
201990,05 %28,11 %26,91 %
201893,53 %37,76 %36,42 %
201793,24 %35,42 %20,42 %
201693,85 %27,39 %18,44 %
201590,42 %30,51 %15,50 %
201492,73 %29,18 %11,99 %
201392,59 %36,10 %20,14 %
201293,90 %33,24 %54,43 %
201199,10 %−45,96 %−49,78 %
201099,56 %−21,13 %−22,66 %
200999,74 %−19,53 %−17,94 %
2008100,00 %−36,55 %−33,19 %
2007100,00 %−92,00 %−85,60 %
200687,30 %−171,43 %−161,90 %
200586,36 %−187,88 %−143,94 %
200491,38 %3,45 %24,14 %

Regeneron Pharmaceuticals delnica promet, EBIT, dobiček na delnico

Regeneron Pharmaceuticals-promet na delnico tako pokaže, koliko prometa je Regeneron Pharmaceuticals v določenem obdobju ustvaril na posamezno delnico. EBIT na delnico kaže, koliko operativnega dobička pripada na posamezno delnico. Dobiček na delnico pokaže, koliko dobička pripada na vsako delnico.

  • 3 leta

  • 5 let

  • 10 let

  • 25 let

  • Max

Prihodek na delnico
EBIT na delnico
Dobiček na delnico
Podrobnosti

Prihodki, EBIT in dobiček na delnico

ⓘ

Prihodki na delnico

Prihodki na delnico predstavljajo celotni prihodek, ki ga je Regeneron Pharmaceuticals ustvaril, deljen s številom izdanih delnic. Je ključni kazalnik, saj odraža sposobnost podjetja, da generira prihodke, in kaže potencial za rast in širitev. Letna primerjava prihodkov na delnico omogoča vlagateljem analizo doslednosti prihodkov podjetja in predvidevanje prihodnjih trendov.

EBIT na delnico

EBIT na delnico ponazarja dobiček Regeneron Pharmaceuticals pred obrestmi in davki ter ponuja vpogled v operativno donosnost, brez upoštevanja učinkov kapitalske strukture in davčnih stopenj. Primerjava z prihodki na delnico omogoča ocene učinkovitosti pretvorbe prodaje v dobiček. Nenehna rast EBIT na delnico skozi leta poudarja operativno učinkovitost in dobičkonosnost.

Dobiček na delnico

Dobiček na delnico ali EPS (Earnings Per Share) prikazuje delež dobička Regeneron Pharmaceuticals, ki se dodeli vsaki delnici osnovnega kapitala. Je ključnega pomena za ocenjevanje dobičkonosnosti in finančnega zdravja. Z primerjavo prihodkov in EBIT na delnico lahko vlagatelji vidijo, kako učinkovito podjetje pretvarja prihodke in operativni dobiček v čisti dohodek.

Pričakovane vrednosti

Pričakovane vrednosti so napovedi za prihodke, EBIT in dobiček na delnico za prihodnja leta. Ta pričakovanja, ki temeljijo na zgodovinskih podatkih in analizi trga, pomagajo vlagateljem pri strategiji njihovih naložb, oceni prihodnjega delovanja Regeneron Pharmaceuticals in napovedi prihodnjih delniških tečajev. Ključno pa je upoštevanje tržnih volatilnosti in negotovosti, ki lahko vplivajo na te napovedi.

Regeneron Pharmaceuticals Promet, dobiček in EBIT na delnico – zgodovina

DatumRegeneron Pharmaceuticals Prihodek na delnicoRegeneron Pharmaceuticals EBIT na delnicoRegeneron Pharmaceuticals Dobiček na delnico
2029e182,19 undefined0 undefined73,86 undefined
2028e171,86 undefined0 undefined67,00 undefined
2027e162,18 undefined0 undefined61,48 undefined
2026e151,97 undefined0 undefined55,97 undefined
2025e142,36 undefined0 undefined49,94 undefined
2024e131,09 undefined0 undefined45,95 undefined
2023115,37 undefined38,13 undefined34,77 undefined
2022106,78 undefined43,81 undefined38,05 undefined
2021143,50 undefined79,88 undefined72,10 undefined
202073,89 undefined31,10 undefined30,55 undefined
201968,37 undefined19,22 undefined18,40 undefined
201858,36 undefined22,03 undefined21,25 undefined
201750,62 undefined17,93 undefined10,34 undefined
201641,90 undefined11,47 undefined7,72 undefined
201535,69 undefined10,89 undefined5,53 undefined
201424,96 undefined7,28 undefined2,99 undefined
201318,96 undefined6,85 undefined3,82 undefined
201211,98 undefined3,98 undefined6,52 undefined
20114,90 undefined−2,25 undefined−2,44 undefined
20105,53 undefined−1,17 undefined−1,25 undefined
20094,74 undefined−0,93 undefined−0,85 undefined
20083,01 undefined−1,10 undefined−1,00 undefined
20071,89 undefined−1,74 undefined−1,62 undefined
20061,09 undefined−1,86 undefined−1,76 undefined
20051,18 undefined−2,21 undefined−1,70 undefined
20043,11 undefined0,11 undefined0,75 undefined

Regeneron Pharmaceuticals Delnica in analiza delnic

Regeneron Pharmaceuticals Inc. is an American biotechnology company founded in 1988 by Leonard Schleifer. The company is headquartered in Tarrytown, New York and employs approximately 8,500 people worldwide. Regeneron is known for its research in the areas of cancer therapies, eye diseases, and asthma. Regeneron operates a business model based on the research and development of biotechnological drugs. The company invests heavily in research and seeks new compounds that can fight inflammation and cancer. Regeneron develops its products using the reverse transcriptase polymerase chain reaction (RT-PCR), a method for amplifying RNA molecules into DNA. This method allows for the rapid production and analysis of large amounts of genetic material. The company is divided into several divisions, including ophthalmology, inflammatory diseases, oncology, and neurology. Regeneron also produces a wide range of biopharmaceutical products, including antibodies, interleukins, enzymes, and fusion proteins. One of Regeneron's most popular products is EYLEA (Aflibercept), a medication used to treat retinal diseases such as age-related macular degeneration. EYLEA has been on the market since 2011 and has proven to be highly effective. The medication is a blockbuster for Regeneron and accounts for a significant portion of its product revenue. Another important product from Regeneron is Dupixent (Dupilumab), a medication used to treat atopic dermatitis and severe asthma. The medication has been on the market since 2017 and has quickly established itself as a key treatment for asthma. Dupixent is produced in collaboration with Sanofi. Regeneron has also conducted promising research in the field of oncology. The company has developed a range of cancer therapies that are in the clinical phase of development. One example is the antibody Libtayo, which is used to treat squamous cell carcinomas. In its recent history, Regeneron has played a major role in the research and development of antibodies for the treatment of COVID-19. Regeneron was the first company to receive funding from the US government for the development of an antibody cocktail for the treatment of COVID-19. The medication, consisting of the antibodies Casirivimab and Imdevimab, was granted emergency use authorization by the US Food and Drug Administration in November 2020. Regeneron also has an extensive partnership with pharmaceutical company Sanofi. The two companies have jointly developed products such as Praluent (Alirocumab), a medication used to lower cholesterol levels, and Kevzara (Sarilumab), a medication used to treat rheumatoid arthritis. Overall, in recent years, Regeneron has built a strong position as a leading biotechnology company. The company has an impressive product pipeline and has developed a wide range of important medications. Regeneron continues to work on the development of new therapies and has the potential to play a significant role in the biotechnology industry in the coming years. Regeneron Pharmaceuticals je eno izmed najbolj priljubljenih podjetij na Eulerpool.com.

Regeneron Pharmaceuticals Prihodki po segmentih

V poslovnem poročilu delnice Regeneron Pharmaceuticals (US75886F1075, 881535, REGN) so prihodki razdeljeni na 1 segmentov: 1. Medicines. Delnica Regeneron Pharmaceuticals (WKN: 881535, ISIN: US75886F1075, simbol oznake: REGN) je vodilna naložba za vlagatelje, ki so zainteresirani za udeležbo v sektorju Health Care.

  • 100 % Medicines

Regeneron Pharmaceuticals Ocenjevanje po Fair Value

Podrobnosti

Fair Value

ⓘ

Razumevanje Fair Value

Fair Value delnice nudi vpogled v to, ali je delnica trenutno podcenjena ali precenjena. Izračuna se na podlagi dobička, prometa ali dividende in nudi celovit pogled na notranjo vrednost delnice.

Dobičkonosni Fair Value

Ta se izračuna tako, da se dohodek na delnico pomnoži s povprečnim P/E razmerjem izbranih preteklih let za izračun povprečja (glajenje). Če je Fair Value višji od trenutne tržne cene, to kaže, da je delnica podcenjena.

Primer za leto 2022

Fair Value dobiček 2022 = Dobiček na delnico 2022 / Povprečno P/E razmerje 2019 – 2021 (glajenje 3 let)

Prometni Fair Value

Izračuna se tako, da se promet na delnico pomnoži s povprečnim P/S razmerjem izbranih preteklih let za izračun povprečja (glajenje). Delnica se smatra za podcenjeno, kadar Fair Value presega trenutno tržno vrednost.

Primer za leto 2022

Fair Value promet 2022 = Promet na delnico 2022 / Povprečno P/S razmerje 2019 – 2021 (glajenje 3 let)

Dividendenbasierter Fair Value

Ta vrednost se ugotovi tako, da se dividenda na delnico deli s povprečnim donosom dividende izbranih preteklih let za izračun povprečja (glajenje). Višji Fair Value od tržne cene nakazuje na podcenjeno delnico.

Primer za leto 2022

Fair Value dividende 2022 = Dividenda na delnico 2022 * Povprečni donos dividende 2019 - 2021 (glajenje 3 let)

Pričakovanja in napovedi

Prihodnja pričakovanja podajajo potencialne poti za gibanje delniških cen in pomagajo vlagateljem pri odločanju. Pričakovane vrednosti so napovedane številke Fair Value, ob upoštevanju trendov rasti ali padanja pri dobičku, prometu ali dividendah.

Vergleichende Analyse

Primerjava Fair Value, na osnovi dobička, prometa in dividend daje celosten pregled finančnega zdravja delnice. Spremljanje letnih in medletnih sprememb prispeva k razumevanju stalnosti in zanesljivosti delovanja delnic.

Regeneron Pharmaceuticals Ocena glede na zgodovinsko razmerje cena/dobiček, EBIT in prihodek od prodaje

Regeneron Pharmaceuticals Število delnic

Število delnic pri družbi Regeneron Pharmaceuticals v letu 2023 je bilo — To pove, na koliko delnic je razdeljen 113,7 mio.. Ker so delničarji lastniki podjetja, vsaka delnica predstavlja majhen delež lastništva v podjetju.

  • 3 leta

  • 5 let

  • 10 let

  • 25 let

  • Max

Število delnic
Podrobnosti

Prihodki, EBIT in dobiček na delnico

ⓘ

Prihodki na delnico

Prihodki na delnico predstavljajo celotni prihodek, ki ga je Regeneron Pharmaceuticals ustvaril, deljen s številom izdanih delnic. Je ključni kazalnik, saj odraža sposobnost podjetja, da generira prihodke, in kaže potencial za rast in širitev. Letna primerjava prihodkov na delnico omogoča vlagateljem analizo doslednosti prihodkov podjetja in predvidevanje prihodnjih trendov.

EBIT na delnico

EBIT na delnico ponazarja dobiček Regeneron Pharmaceuticals pred obrestmi in davki ter ponuja vpogled v operativno donosnost, brez upoštevanja učinkov kapitalske strukture in davčnih stopenj. Primerjava z prihodki na delnico omogoča ocene učinkovitosti pretvorbe prodaje v dobiček. Nenehna rast EBIT na delnico skozi leta poudarja operativno učinkovitost in dobičkonosnost.

Dobiček na delnico

Dobiček na delnico ali EPS (Earnings Per Share) prikazuje delež dobička Regeneron Pharmaceuticals, ki se dodeli vsaki delnici osnovnega kapitala. Je ključnega pomena za ocenjevanje dobičkonosnosti in finančnega zdravja. Z primerjavo prihodkov in EBIT na delnico lahko vlagatelji vidijo, kako učinkovito podjetje pretvarja prihodke in operativni dobiček v čisti dohodek.

Pričakovane vrednosti

Pričakovane vrednosti so napovedi za prihodke, EBIT in dobiček na delnico za prihodnja leta. Ta pričakovanja, ki temeljijo na zgodovinskih podatkih in analizi trga, pomagajo vlagateljem pri strategiji njihovih naložb, oceni prihodnjega delovanja Regeneron Pharmaceuticals in napovedi prihodnjih delniških tečajev. Ključno pa je upoštevanje tržnih volatilnosti in negotovosti, ki lahko vplivajo na te napovedi.

Za Regeneron Pharmaceuticals trenutno žal ni na voljo nobenih ciljnih vrednosti in napovedi.

Regeneron Pharmaceuticals Dobičkovna presenečenja

DatumOcena dobička na delnicoEPS dejanskiČetrtletje poročanja
30. 6. 202410,83 11,56  (6,79 %)2024 Q2
31. 3. 202410,29 9,55  (−7,23 %)2024 Q1
31. 12. 202310,95 11,86  (8,36 %)2023 Q4
30. 9. 202310,93 11,59  (6,01 %)2023 Q3
30. 6. 202310,04 10,24  (1,99 %)2023 Q2
31. 3. 20239,75 10,09  (3,50 %)2023 Q1
31. 12. 202210,23 12,56  (22,77 %)2022 Q4
30. 9. 20229,67 11,14  (15,25 %)2022 Q3
30. 6. 20229,02 9,77  (8,33 %)2022 Q2
31. 3. 20229,93 8,93  (−10,09 %)2022 Q1
1
2
3
4
5
...
10

Eulerpool ESG ocena za delnico Regeneron Pharmaceuticals

Eulerpool World ESG Rating (EESG©)

82/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

47

Okolje (Environment)

Neposredne emisije
64.800
Posredne emisije iz kupljene energije
38.100
Posredne emisije znotraj verige vrednosti.
821.761
Emisije CO₂
102.900
Strategija zmanjševanja CO₂
✅
Ogljična energija
❌
Atomkraft
❌
Poskusi na živalih
✅
Pelz & Leder
—
Pesticidi
—
Palmovo olje
—
Tobak
❌
Genska tehnologija
❌
Koncept podnebja
—
Trajnostno gozdarstvo
—
Predpisi o recikliranju
✅
Okolju prijazna embalaža
❌
Nevarne snovi
✅
Poraba goriva in učinkovitost
✅
Poraba in učinkovitost vode
✅

Socialno (Social)

Delež zaposlenih žensk49
Delež žensk v upravljanju—
Delež azijskih zaposlenih—
Delež azijskega upravljanja—
Delež hispanskih/latinskih zaposlenih—
Delež hispansko/latino vodstva—
Delež črnskih zaposlenih—
Delež črnega vodstva—
Delež belih zaposlenih69
Delež belskega managementa67
Vsebine za odrasle❌
Alkohol❌
obramba—
orožje
❌
igralništvo❌
vojaške pogodbe❌
Koncept človekovih pravic✅
Koncept varstva podatkov—
Varstvo pri delu in zdravje✅
katoliški✅

Upravljanje podjetja (Governance)

Porocilo o trajnostnem razvoju✅
Vključevanje deležnikov✅
Pravilnik o odpoklicu❌
Kartelno pravo❌

Priznana ocena Eulerpool ESG je strogo avtorsko zaščitena intelektualna lastnina podjetja Eulerpool Research Systems. Vsakršna neavtorizirana uporaba, posnemanje ali kršenje bo odločno preganjano in lahko privede do obsežnih pravnih posledic. Za licence, sodelovanje ali pravice uporabe se obrnite neposredno preko našega Kontaktni obrazec k nam.

Regeneron Pharmaceuticals Delnica struktura lastništva

%
Ime
Delnice
Sprememba
Datum
9,06191 % Fidelity Management & Research Company LLC9.988.945435.05731. 12. 2023
7,97657 % The Vanguard Group, Inc.8.792.57539.50531. 12. 2023
5,13826 % BlackRock Institutional Trust Company, N.A.5.663.900−283.71231. 12. 2023
5,07177 % JP Morgan Asset Management5.590.613−169.90731. 12. 2023
4,65435 % Capital World Investors5.130.48523.14631. 12. 2023
4,44639 % State Street Global Advisors (US)4.901.25172.14531. 12. 2023
2,64535 % Capital International Investors2.915.972−58.36631. 12. 2023
2,14795 % Dodge & Cox2.367.680−5.31831. 12. 2023
2,13573 % Geode Capital Management, L.L.C.2.354.21734.23131. 12. 2023
1,83981 % Invesco Capital Management (QQQ Trust)2.028.0196.99231. 3. 2024
1
2
3
4
5
...
10

Regeneron Pharmaceuticals Upravni odbor in nadzorni svet

Dr. Neil Stahl66
Regeneron Pharmaceuticals Executive Vice President - Research and Development
Plačilo: 9,14 mio.
Mr. Andrew Murphy65
Regeneron Pharmaceuticals Executive Vice President - Research
Plačilo: 9,12 mio.
Mr. Daniel Van Plew50
Regeneron Pharmaceuticals Executive Vice President, General Manager - Industrial Operations and Product Supply
Plačilo: 8,85 mio.
Mr. Joseph LaRosa64
Regeneron Pharmaceuticals Executive Vice President, General Counsel, Secretary
Plačilo: 7,13 mio.
Dr. Leonard Schleifer70
Regeneron Pharmaceuticals Co-Chairman of the Board, President, Chief Executive Officer, Founder (od 1988)
Plačilo: 7,00 mio.
1
2
3
4
...
5

Regeneron Pharmaceuticals Dobavna veriga

ImeRazmerjeDvotedenska korelacijaMesečna korelacijaTrimesečna korelacijaŠestmesečna korelacijaEnoletna korelacijaDvoletna korelacija
Teva Pharmaceutical Inds Delnica
Teva Pharmaceutical Inds
dobaviteljStranka0,890,970,760,59-0,42-0,44
Alnylam Pharmaceuticals Delnica
Alnylam Pharmaceuticals
dobaviteljStranka0,890,810,430,18-0,010,43
AmerisourceBergen Corporation Delnica
AmerisourceBergen Corporation
dobaviteljStranka0,860,890,940,650,670,53
Bayer Delnica
Bayer
dobaviteljStranka0,860,880,910,740,400,20
Zoetis Inc. Delnica
Zoetis Inc.
dobaviteljStranka0,860,87-0,16-0,320,230,47
Mitsubishi Chemical Holdings Corporation Delnica
Mitsubishi Chemical Holdings Corporation
dobaviteljStranka0,780,67-0,280,22--
Sanofi Delnica
Sanofi
dobaviteljStranka0,750,270,350,500,24-
Kiniksa Pharmaceuticals A Delnica
Kiniksa Pharmaceuticals A
dobaviteljStranka0,690,930,27-0,16-0,48-0,49
Ultragenyx Pharmaceutical Delnica
Ultragenyx Pharmaceutical
dobaviteljStranka0,680,930,750,25-0,37-0,74
McKesson Corporation Delnica
McKesson Corporation
dobaviteljStranka0,670,780,910,670,670,52
1
2
3
4

Pogosta vprašanja o delnici Regeneron Pharmaceuticals

What values and corporate philosophy does Regeneron Pharmaceuticals represent?

Regeneron Pharmaceuticals Inc is a leading biotechnology company that values innovation, integrity, and collaboration. With a corporate philosophy centered around science-driven discoveries and patient-focused solutions, Regeneron aims to improve lives through its research and development of therapeutic products. They prioritize the use of cutting-edge technologies to address unmet medical needs and strive to deliver impactful medicines to patients worldwide. Regeneron's commitment to transparency, ethical practices, and scientific excellence has established its reputation as a trusted and reliable healthcare partner.

In which countries and regions is Regeneron Pharmaceuticals primarily present?

Regeneron Pharmaceuticals Inc primarily operates in various countries and regions around the world. The company has a global presence with key markets in the United States, Europe, and other international locations. Through its strong partnerships and collaborations, Regeneron has expanded its reach and established a significant presence in the biopharmaceutical industry. With its dedication to scientific innovation and breakthrough treatments, Regeneron Pharmaceuticals Inc continues to make a meaningful impact on patients' lives worldwide.

What significant milestones has the company Regeneron Pharmaceuticals achieved?

Regeneron Pharmaceuticals Inc. has achieved several significant milestones since its inception. Notably, the company received FDA approval for its groundbreaking drug, EYLEA®, in 2011, which revolutionized the treatment of age-related macular degeneration. Regeneron also gained recognition for the development of its therapy, Dupixent®, for atopic dermatitis, asthma, and other allergic conditions. In addition, the company has made significant advancements in the field of immuno-oncology with its innovative drug, Libtayo®, approved for the treatment of certain types of skin and lung cancers. Regeneron continues to drive progress in the biopharmaceutical industry by focusing on novel research and development initiatives.

What is the history and background of the company Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals Inc, founded in 1988, is a renowned American biotechnology company specializing in the discovery, development, and commercialization of innovative medicines. Headquartered in Tarrytown, New York, Regeneron has a rich history of pioneering scientific breakthroughs. The company's success can be attributed to its robust research and development initiatives, focusing on various therapeutic areas such as oncology, ophthalmology, cardiovascular diseases, and rare genetic disorders. Regeneron's remarkable achievements include the development of EYLEA® (a leading treatment for retinal diseases) and the groundbreaking antibody cocktail, REGN-COV2, used for COVID-19 treatment. Renowned for its dedication to rigorous scientific research, Regeneron Pharmaceuticals Inc has established itself as a leader in the biopharmaceutical industry.

Who are the main competitors of Regeneron Pharmaceuticals in the market?

The main competitors of Regeneron Pharmaceuticals Inc in the market include major pharmaceutical companies like Roche Holding AG, Amgen Inc, and Pfizer Inc. These companies are also involved in the development and commercialization of biopharmaceutical products, competing within the same therapeutic areas as Regeneron.

In which industries is Regeneron Pharmaceuticals primarily active?

Regeneron Pharmaceuticals Inc is primarily active in the biopharmaceutical industry.

What is the business model of Regeneron Pharmaceuticals?

The business model of Regeneron Pharmaceuticals Inc. revolves around the research, development, and commercialization of innovative biopharmaceutical products. Regeneron focuses on discovering, designing, and manufacturing novel medicines that address unmet medical needs. The company employs advanced technologies, including monoclonal antibody platforms and genetically modified mice, to develop therapies across various therapeutic areas, such as ophthalmology, oncology, and inflammatory diseases. By continuously investing in research and strategic collaborations, Regeneron strives to deliver life-changing treatments, improve patient outcomes, and become a leading force in the biopharmaceutical industry. Visit our website for more information about Regeneron Pharmaceuticals Inc. and its business model.

Kakšno PE razmerje ima Regeneron Pharmaceuticals 2024?

Razmerje cena/dobiček Regeneron Pharmaceuticals je 25,40.

Kakšen je KUV Regeneron Pharmaceuticals 2024?

Koeficient Regeneron Pharmaceuticals cene in prihodkov je 8,90.

Kakšen je AlleAktien kakovostni rezultat za Regeneron Pharmaceuticals?

AlleAktien kakovostni rezultat za Regeneron Pharmaceuticals je 8/10.

Kakšen je promet podjetja Regeneron Pharmaceuticals 2024?

pričakovana Regeneron Pharmaceuticals promet je 14,45 milijard USD.

Kakšen je dobiček od Regeneron Pharmaceuticals 2024?

Dobiček pričakovana Regeneron Pharmaceuticals je 5,07 milijard USD.

Kaj počne Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals is a biotechnology company based in the United States that focuses on researching, developing, and marketing medications. It was founded in 1988 by Leonard Schleifer and George Yancopoulos and is headquartered in Tarrytown, New York. Regeneron is divided into various business divisions that address different medical conditions. This includes the field of ophthalmology, where Regeneron has developed the medication Eylea®, an effective treatment for age-related macular degeneration and other eye diseases. The sales in this area amounted to approximately $7.7 billion in 2020. Another important area is oncology, where Regeneron has developed the cancer medication Libtayo®, which is used to treat skin cancer and lung cancer. The sales in this area amounted to approximately $340 million in 2020. Regeneron is also involved in inflammation diseases, genetic diseases, and infectious diseases. The company has several promising medications in development in these areas, including a treatment for COVID-19. Regeneron collaborates closely with various partners in the pharmaceutical and biotech industry. This includes the British pharmaceutical company Sanofi, with whom Regeneron has already brought several successful medications to the market. The company also has partnerships with other major industry players such as Bayer and Roche. Regeneron places great emphasis on research and development and invests a significant amount of money in this area. In 2020, the R&D expenditure amounted to approximately $3.7 billion, which is about 40 percent of the total revenue. The company employs a large number of scientists and researchers who are constantly working on new medications. Regeneron also values the promotion of young talent. The company has established an extensive scholarship program specifically targeted at students and young scientists. This ensures that highly qualified professionals will be available in the future to further advance the company. In summary, Regeneron's business model specializes in research and development of new medications. The company works closely with various partners and has already brought several promising medications to the market. Regeneron places great importance on promoting young talent and building a highly qualified team of scientists and researchers. Regeneron Pharmaceuticals is a US biotechnology company that specializes in the research, development, and marketing of medications. The company was founded in 1988 by Leonard Schleifer and George Yancopoulos and is headquartered in Tarrytown, New York. Regeneron is divided into several business areas that deal with different medical conditions. This includes the field of ophthalmology, in which Regeneron has developed the effective drug Eylea® for age-related macular degeneration and other eye diseases. Sales in this area were around $7.7 billion in 2020. Another important area is oncology, in which Regeneron has developed the cancer drug Libtayo®, which is used to treat skin cancer and lung cancer. Sales in this area were around $340 million in 2020. Other business areas of Regeneron include inflammatory diseases, genetic diseases, and infectious diseases. In these areas, the company has already developed several promising drugs, including a treatment for COVID-19. Regeneron works closely with various partners in the pharmaceutical and biotech industry. This includes the British pharmaceutical company Sanofi, with which Regeneron has already successfully launched several drugs on the market. The company also has partnerships with other major industry players such as Bayer and Roche. Regeneron places great emphasis on research and development and invests a significant amount of money in this area. In 2020, R&D spending was around $3.7 billion, approximately 40 percent of total revenue. The company employs a large number of scientists and researchers who are constantly working on new drugs. Regeneron also places great importance on promoting young talent. The company has launched an extensive scholarship program specifically targeting students and young scientists. This is to ensure that highly qualified professionals are available in the future to further advance the company. In conclusion, Regeneron's business model specializes in the research and development of new medications. The company works closely with various partners and has already launched several promising drugs on the market. Regeneron places great importance on promoting young talent and building a highly qualified team of scientists and researchers.

Kako visoka je Regeneron Pharmaceuticals dividenda?

Regeneron Pharmaceuticals izplača dividendo v višini 0 USD, razdeljeno na izplačil letno.

Kako pogosto Regeneron Pharmaceuticals izplača dividendo?

Dividende za Regeneron Pharmaceuticals trenutno ni mogoče izračunati ali pa podjetje ne izplačuje dividend.

Kaj je Regeneron Pharmaceuticals ISIN?

ISIN od Regeneron Pharmaceuticals je US75886F1075.

Kaj je Regeneron Pharmaceuticals WKN?

WKN od Regeneron Pharmaceuticals je 881535.

Kaj je Regeneron Pharmaceuticals oznaka indeksa?

Oznaka delnice Regeneron Pharmaceuticals je REGN.

Koliko dividende izplača Regeneron Pharmaceuticals?

V zadnjih 12 mesecih je Regeneron Pharmaceuticals izplačal dividendo v višini . To ustreza približni donosnosti dividend . V prihajajočih 12 mesecih bo Regeneron Pharmaceuticals predvidoma izplačal dividendo v višini 0 USD.

Kakšen je donos dividend od Regeneron Pharmaceuticals?

Trenutni donos od dividend za Regeneron Pharmaceuticals znaša .

Kdaj Regeneron Pharmaceuticals izplača dividend?

Regeneron Pharmaceuticals izplačuje četrtletno dividendo. Ta se izplačuje v mesecih .

Kako varna je dividenda od Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals je v zadnjih 0 letih vsako leto izplačeval dividend.

Kakšna je dividenda od Regeneron Pharmaceuticals?

V naslednjih 12 mesecih se pričakuje dividende v višini 0 USD. To ustreza dividendnemu donosu 0 %.

V katerem sektorju se nahaja Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals je razvrščen v sektor 'Zdravje'.

Wann musste ich die Aktien von Regeneron Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

Da si prejel zadnjo dividendo Regeneron Pharmaceuticals z dne 9. 9. 2024 v višini 0 USD, si moral imeti delnico v depoju pred dnevom brez pravice do dividende (Ex-Tag) 9. 9. 2024.

Kdaj je Regeneron Pharmaceuticals izplačal zadnjo dividendo?

Zadnje izplačilo dividende je bilo 9. 9. 2024.

Kakšna je bila dividenda od Regeneron Pharmaceuticals v letu 2023?

V letu 2023 je Regeneron Pharmaceuticals 0 USD izplačal kot dividende.

V kateri valuti Regeneron Pharmaceuticals izplača dividendo?

Dividende od Regeneron Pharmaceuticals se izplačujejo v USD.

Druge ključne številke in analize od Regeneron Pharmaceuticals v poglobljenem pregledu

Naša analiza delnic Regeneron Pharmaceuticals Prihodki vključuje pomembne finančne kazalnike, kot so prihodki, dobiček, razmerje cena/dobiček (KGV), razmerje cena/prihodki (KUV), EBIT ter informacije o dividendah. Prav tako preučujemo aspekte, kot so delnice, tržna kapitalizacija, dolgovi, lastniški kapital in obveznosti Regeneron Pharmaceuticals Prihodki. Če iščete podrobnejše informacije o teh temah, na naših podstraneh nudimo obsežne analize: